No profile data available.
Castle Biosciences, Inc. (CSTL) is a healthcare company in the DNA testing equipment industry, based in Friendswood, United States, with about 1,002 full-time employees.
It reported revenue of $344.23 million for fiscal year 2025, up 3.7% from fiscal year 2024, and net income of -$24.16 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $103.55 million, up 20.1% from a year before. Its market capitalization was $1.05 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Castle Biosciences reported $344.23 million in revenue for fiscal year 2025, up 3.7% from $332.07 million in fiscal year 2024. In Q2 2026 revenue was $103.55 million.
$1.05 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (DNA testing equipment) include Adaptive Biotechnologies Corporation (ADPT), Veracyte, Inc. (VCYT), CareDx, Inc (CDNA), Myriad Genetics, Inc. (MYGN).